Should You Buy AbbVie Stock Hand Over Fist Before April 29?

AbbVie is set to report Q1 earnings on April 29, with expected net revenue of about $14.7 billion, implying roughly 10% year-over-year growth. The article highlights strong momentum for Skyrizi and Rinvoq, but warns that Humira’s decline and weaker Imbruvica sales, including government price negotiations, could offset results. Longer term, AbbVie remains attractive for income investors thanks to its dividend streak, now at 54 consecutive annual increases.

Analysis

ABBV is at an inflection where the market is less focused on absolute growth than on the durability of the post-Humira mix shift. The key second-order read-through is whether immunology growth is becoming self-sustaining enough to offset a maturing legacy portfolio; if yes, the stock can rerate even without upside to consensus EPS, because the market will start capitalizing the new franchise at a higher terminal multiple.

The main risk is not a bad quarter in isolation, but evidence that growth is increasingly concentrated in a small number of assets while the rest of the book degrades faster than expected. That would compress the narrative from “successful transition” to “single-asset dependency,” which is exactly the type of setup that tends to keep a pharma multiple capped despite attractive cash returns. Imbruvica pressure is also a useful signal: if pricing actions and competition are already visible in reported numbers, the market may extrapolate that other aging franchises are closer to their own decline curves than bulls assume.

Contrarianly, the dividend is likely underappreciated as a floor because it forces a different buyer base into the stock on weakness. In a volatile tape, ABBV can trade like a bond proxy with embedded call option on pipeline execution; that combination often limits drawdowns more than consensus expects, especially if management reaffirms the full-year guide. The setup favors trading the event around guidance quality rather than simply the headline revenue print.

Key Decisions for Investors

• Hold or add to ABBV into earnings only if you can tolerate event risk; upside is best if management raises confidence on full-year growth cadence, with a likely 5-8% post-print move if guidance de-risks the transition story.
• Buy ABBV downside protection: 1-2 month put spreads financed by selling out-of-the-money calls, targeting a mild negative surprise scenario where legacy erosion overwhelms growth; skew is attractive because downside is more about narrative damage than insolvency risk.
• Pair trade: long ABBV / short a basket of slower-growth large-cap pharma names with weaker pipeline visibility over the next 3-6 months; the market should reward clearer post-patent transition visibility.
• If ABBV gaps down on a solid dividend-safe quarter but weak tone on non-core franchises, use the drawdown to accumulate for income, not momentum; the risk/reward improves materially on any 7-10% post-earnings selloff.
• Avoid chasing the pre-earnings move in NVDA/INTC/NFLX references embedded in the article; they are marketing noise here, not a catalyst set, so the only actionable event risk is ABBV guidance and franchise mix.